Physician profile
Blessilda Liu
NPI 1720022601
$6,516.03
in general payments reported to CMS, 2019-2025
25 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $991 · 2021: $1,128 · 2022: $964 · 2023: $616 · 2024: $593 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.15 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,319.07 | 2019-2025 | Jardiance |
| Amgen INC. | $1,191.74 | 2019-2025 | Repatha, Evenity, Otezla |
| Astellas Pharma US INC | $606.21 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $514.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $467.38 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $464.01 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $407.14 | 2023-2025 | |
| Novo Nordisk INC | $268.33 | 2019-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $147.17 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $132.14 | 2024-2025 | Gemtesa |
| Amarin Pharma, INC. | $129.25 | 2020-2021 | |
| Boston Scientific Corporation | $125.36 | 2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $112.11 | 2020-2025 | Nexletol |
| Pfizer INC. | $106.16 | 2020-2024 | |
| Exact Sciences Corporation | $83.99 | 2023-2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $66.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $61.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $44.73 | 2019-2020 | |
| Abbott Laboratories | $39.54 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $38.91 | 2019 | |
| Genentech USA, INC. | $31.03 | 2019-2020 | |
| Allergan, INC. | $30.13 | 2020 | |
| Eisai INC. | $28.90 | 2021-2022 | |
| Biogen, INC. | $17.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blessilda Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.